Company Overview of Oryzon Genomics S.A.
Oryzon Genomics S.A., a biopharmaceutical company, develops and commercializes biomarkers identified through genomics and proteomics in the fields of diagnostics, personalized medicine, and therapy. Its products pipeline comprises GynEC-DX, a diagnostic test for endometrial cancer; ColoBRAF, a genetic test that verifies the presence of the BRAF-V600E mutation in MSI-H tumors; and Cxbladder, a non-invasive bladder cancer diagnostic test. The company also develops small molecules and monoclonal antibodies for various indications, including leukemia and other cancers, PD/AD and other dementias, Huntington, viral infections, squamous cell cancer, prostate cancer, and endometrial cancer. In addit...
Sant Ferran 74
Cornellà de Llobregat
Founded in 2000
Key Executives for Oryzon Genomics S.A.
Co-Founder, Chairman, Chief Executive Officer, President and Member of Financial Advisory Board
Co-Founder, Scientific Director and Director
Global Chief Financial Officer, Executive Vice President, Director and Chairman of Audit Committee
Chief Intellectual Property Officer
Director of Business Development
Compensation as of Fiscal Year 2015.
Oryzon Genomics S.A. Key Developments
Oryzon Genomics S.A. Proposes Amendments to its Articles of Association
May 29 15
Oryzon Genomics S.A. at the Annual General Meeting to be held on June 30, 2015, proposed amendment of Articles 16 and 23 to adapt to changes concerning the system of the General Meeting and its powers, amendment of Articles 20a, 22 and 24 to adapt to changes concerning the system the Board of Directors and the status of its directors and amendment of article 18 to include a technical improvement.
Oryzon Genomics S.A., Annual General Meeting, Jun 30, 2015
May 29 15
Oryzon Genomics S.A., Annual General Meeting, Jun 30, 2015., at 10:00 Central European Standard Time. Location: Cornellà de Llobregat. Agenda: To consider and approve abridged financial statements and approval, if any, of the proposed application of results for the fiscal year ended December 31, 2014; to consider amendment to Articles 16, 23, 20a, 22 and 24; to consider amendment of article 18 to include a technical improvement; to consider approval, if any, of the capital increase by raising the value par value of shares currently outstanding; to consider capital increase by issuing new excluding shares and preferential subscription right; to consider ratification of the contract signed by the company accepting the conditions for Grant funding in biotechnology; to consider agreement approved by the Board of Directors Society on the relationship of Mr. and Mrs. Carlos Buesa. Tamara Maes with the company; and to consider delegation of powers point.
Oryzon Genomics SA Appoints Greg Weaver as Executive Vice President and Global Chief Financial Officer
Jan 12 15
Oryzon Genomics SA announced the appointment of Gregory L. Weaver as executive vice president and chief financial officer, effective January 12, 2015. Weaver will report directly to Carlos Buesa, president and chief executive officer of Oryzon, and will be based at Oryzon's U.S. headquarters, located at 245 First Street in Cambridge, MA. Weaver has served as CFO Fibrocell Science. Previous to Fibrocell, Weaver was CFO at Celsion Corp, Poniard Pharmaceuticals and Sirna Therapeutics. He also currently serves as non-executive director of Egalet Corporation and Atossa Genetics. Oryzon's Mr. Enric Rello will remain as CFO in Spain and will continue as part of Oryzon's senior management team to support the company's financial operations in Spain.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|